DA-1241 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

FDA Complete Response Letter puts Disc Medicine Inc.’s bitopertin timeline under pressure

What Humana Inc.’s MaxHealth acquisition signals for Medicare Advantage strategy

What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals

Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates

Read More

4 minute read

Pharma Industry News

MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025

MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies.

byPallavi Madhiraju

June 21, 2025

web analytics